A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects

Inclusion Criteria

• •No significant abnormality on 12-lead ECG at screening, including the following specific requirements: Ventricular rate inside the range 40-90 beats (inclusive) per minute (bpm) at screening, PR interval \<=210milliseconds (msec), No pathological Q waves, QRS interval \>=60 msec and \<=120 msec, the waveforms must enable the QT interval to be clearly defined and the corrected QT interval by Fridericia's method (QTcF) must be \<450msec (machine or manual reading) based on a single ECG value, or an average from three ECGs obtained over a brief recording period.
• •Forced Expiratory Volume in 1 second (FEV1) \>=80% predicted and a FEV1/Forced Vital Capacity (FVC) ratio \>=0.7
• •AST, ALT, ALP and bilirubin \<=1.5x Upper limit of normal (ULN) (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
• •Male/females aged between 18 and 45 years of age (inclusive), at the time of signing the informed consent. Male and female is 1:1.
• •Body weight \>=50 Kilogram (Kg) and Body Mass Index (BMI) within the range 19-24 Kg per square meter (m\^2) (inclusive).
• •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and lung function testing. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator considers the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures and outcome.
• •Subjects who are current non-smokers and have not used any tobacco products in the 6 month period preceding screening and have a pack history of \<=10 pack years.
• •\[Number of pack years = (number of cigarettes per day /20) x number of years smoked\]
• •Capable of giving written informed consent.
• •A female subject is eligible to participate if: she is of child-bearing potential and is abstinent or agrees to use one of the contraception methods for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the chance of pregnancy at that point or She must agree to use contraception until the follow-up visit (i.e. until follow-up visit is complete) or she is on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks should elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method or she is confirmed postmenopausal or permanently sterilised (example \[e.g.\] tubal occlusion, tubal ligation, hysterectomy, bilateral salpingectomy).